NAGE Overview

Niagen Bioscience, Inc. is a global bioscience company dedicated to promoting healthy aging. Its segments include Consumer Products, Ingredients segment, Analytical Reference Standards and Services and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors. The ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and outsourcing facilities. The Analytical Reference Standards and Services segment offer the supply of phytochemical reference standards and other research and development services. The Pharmaceutical segment focuses on the pharmaceutical development of its nicotinamide adenine dinucleotide (NAD) precursor portfolio for potential therapeutic applications in rare diseases.

Wall Street analysts forecast NAGE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NAGE is16.33 USD with a low forecast of 12.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Niagen Bioscience Inc revenue for the last quarter amounts to 31.47M USD, increased 3.26

Niagen Bioscience Inc. EPS for the last quarter amounts to 0.07 USD, increased 16.67

Niagen Bioscience Inc (NAGE) has 117 emplpoyees as of May 10 2026.

Today NAGE has the market capitalization of 332.12M USD.